Research directors mulling mounting expenses and lagging productivity are revisiting the notion of consortia—considering whether and how Big Pharma companies and possibly some of the larger biotech firms might join forces to develop infrastructure and gather data that would benefit the industry broadly, or at least benefit all who contribute to a group effort.
Interest in research consortia seems to be one of the legacies of the Human Genome Project (HGP), which awakened desire...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?